ESMO 2023: Expert Perspectives & Insights into the Testing and Treatment of Melanoma - Episode 11

Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases

December 21, 2023

Michael Postow, MD, John M. Kirkwood, MD, Meredith McKean, MD, MPH, Helen Moon, MD, Sapna Patel, BA, MD

For patients with BRAF-mutated melanoma with asymptomatic brain metastases, immunotherapy, particularly the combination of ipilimumab and nivolumab, is the preferred treatment option due to its effectiveness and durability, as supported by the seven-year follow-up data from the CHECKMATE 204 trial.

EP. 1: The Role of Biomarker Testing in the Management of Metastatic Melanoma

EP. 2: Best Practices for Biomarker Testing in Metastatic Melanoma

EP. 3: Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma

EP. 4: Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation

EP. 5: Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma

EP. 6: Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma

EP. 7: Common Adverse Effects Seen With BRAF/MEK Inhibitor Therapy in Patients With BRAF-Mutated Metastatic Melanoma

EP. 8: Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma

EP. 9: Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial

EP. 10: Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma

Now Viewing

EP. 11: Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases